InMode Ltd

NASDAQ INMD

Data sourced from iex and EODHD
Download Data

InMode Ltd Operating Expense Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -1.06%

InMode Ltd Operating Expense Ratio 5 year CAGR is -1.06% for the Trailing 12 Months (TTM) ending March 31, 2024, a 81.13% change year over year. The operating expense ratio represents the proportion of a company's operating expenses to its revenue. It is calculated by dividing the operating expenses by the revenue. This ratio provides insights into the efficiency of a company's cost structure and its ability to control operating expenses relative to its revenue generation. A lower ratio indicates higher operational efficiency and cost management, while a higher ratio suggests higher operating expenses relative to revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • InMode Ltd Operating Expense Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 40.94%, a 6.96% change year over year.
  • InMode Ltd Operating Expense Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 38.27%, a -17.79% change year over year.
  • InMode Ltd Operating Expense Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 46.55%, a -12.61% change year over year.
  • InMode Ltd Operating Expense Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 53.27%, a -11.53% change year over year.
NASDAQ: INMD

InMode Ltd

CEO Mr. Yair Malca
IPO Date Aug. 8, 2019
Location Israel
Headquarters Tavor Building, Yokne'am, Israel, 2069206
Employees 581
Sector Healthcare
Industry Medical devices
Description

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Similar companies

ABT

Abbott Laboratories

NA

NA

MDT

Medtronic PLC

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email